Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant pseudomonas aeruginosa in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 5863-5870

  Gómez Zorrilla, Silvia ^a   Camoez, Mariana ^a   Tubau, Fe ^a   Periche, Elisabet ^a   Cañizares, Rosario ^a   Dominguez, M Angeles ^a   Ariza, Javier ^a   Peña, Carmen ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CARBAPENEM DERIVATIVE; COLISTIN; ERTAPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EXPOSURE; FEMALE; GENOTYPE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT PSEUDOMONAS AERUGINOSA; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RECTUM; RISK FACTOR; CRITICAL ILLNESS; DRUG EFFECTS; MULTIDRUG RESISTANCE; STATISTICS AND NUMERICAL DATA;

ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; INTENSIVE CARE UNITS; PSEUDOMONAS AERUGINOSA; RISK FACTORS;

EID: 84907258883     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03419-14     Document Type: Article

References (28)

1. Bonten MJ, Bergmans DC, Speijer H, Stobberingh EE. 1999. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Am. J. Respir. Crit. Care Med. 160:1212-1219. http://dx.doi.org/10.1164/ajrccm.l 60.4.9809031.
2. Philippe E, Weiss M, Schultz JM, Yeomans F, Ehrenkraz NJ. 1999. Emergence on highly antibiotic resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin. Perform. Qual. Health Care 7:83-87.
3. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38:670-677. http://dx.doi.org/10.1086/381550.
4. Peña C, Guzmán A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J. 2007. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit endemic carbapenemresistanf Pseudomonas aeruginosa strain in critically ill patients. Antimicrob. Agents Chemother. 51:1967-1971. http://dx.doi.org/10.1128/AAC .01483-06.
5. Suarez C, Peña C, Arch O, Dominguez MA, Tubau F, Juan C, Gavaldá L, Sora M, Oliver A, Pujol M, Ariza J. 2011. A large sustained endemic outbreak of multirésistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect. Dis. 11:272-279. http://dx.doi.org/10.1186/1471-2334-11-272.
6. Cabot G, Ocampo-Sosa AA, Dominguez MA, Gago JF, Juan C, Tubau F, Rodriguez C, Moyà B, Peña C, Martinez-Martinez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2012. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob. Agents Chemother. 56:6349-6357. http://dx.doi.org/10.1128/AAC.01388-12.
7. Mulet X, Cabot G, Ocampo-Sosa AA, Dominguez MA, Zamorano L, Juan C, Tubau F, Rodriguez C, Moyà B, Peña C, Martinez-Martinez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI). 2013. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob. Agents Chemother. 57:5527-5535. http://dx.doi.org /10.1128/AAC.0148113.
8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hin dier JF, Kahimeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18: 268-281. http://dx.doi.Org/10.1111/j.1469-0691.2011.03570.x.
9. Cohen MJ, Block CS, Moses AE, Nir-Paz R. 2014. Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance. Clin. Microbiol. Infect. 20:0188-0196. http://dx.doi.org/10.1111 /1469-0691.12362.
10. Le Gall JR, Loirat P, Alperovitch A, Glaser P, Granthil C, Mathieu D, Mercier P, Thomas R, Villers D. 1984. A simplified acute physiologic score for ICU patients. Crit. Care Med. 12:975-977. http://dx.doi.org/10 .1097/00003246-198411000-00012.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J. Chron. Dis. 40:373-383. http://dx.doi.org/10.1016 /0021-9681(87)90171-8.
12. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Deplano A, Denis O, Poirel L, Hocquet D, Nonhoff C, Byl B, Nordmann P, Vincent JL, Struelens MJ. 2005. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43:1198-1204. http://dx.doi.Org/10.1128/JCM.43.3.1198 -1204.2005.
14. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
15. Curran B, Jonas D, Grudmann H, Pitt T, Dowson CG. 2004. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 42:5644-5649. http://dx .doi.org/10.1128/JCM.42.12.5644-5649.2004.
16. Jolley KA, Chan MS, Maiden MC. 2004. mlstdbNet-distributed multilocus sequence typing (MLST) databases. BMC Bioinformatics 5:86. http: //dx.doi.org/10.1186/1471-2105-5-86.
17. Peña C, Suarez C, Tubau F, Juan C, Moya B, Dominguez MMA, Oliver A, Pujol M, Ariza J. 2009. Nosocomial outbreak of a non-cefepime-susceptible ceftazidime susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 ß-lacta- mase. J. Clin. Microbiol. 47:2381-2387. http://dx.doi.org/10.1128/JCM .00094 09.
18. Vollaard EJ, Clasener HAL. 1994. Colonization resistance. Antimicrob. Agents Chemother. 38:409-414. http://dx.doi.Org/10.1128/AAC.38.3 .409.
19. Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, Lucet JC, Corvec S. 2010. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn. Microbiol. Infect. Dis. 66:1-6. http://dx.doi.org/10 .1016/j.diagmicrobio.2009.08.014.
20. Cao B, Wang H, Sun H, Zhu Y, Chen M. 2004. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa. J. Hosp. Infect. 57:112-118. http://dx.doi.org/]0.]0]6/j.jhin.2004.03.021.
21. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daurès JP, Sotto A. 2004. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J. Hosp. Infect. 57:209-216. http://dx .doi,org/10.1016/j.jhin,2004,03,022.
22. Martínez JA, Delgado E, Martí S, Marco F, Vila J, Mensa J, Torres A, Codina C, Trilla A, Soriano A, Alquezar A, Castro P, Nicolás JM. 2009. Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med. 35:439-447. http://dx.doi.org/10.1007/s00134-008 -1326-y.
23. Livermore DM, Mushtaq S, Warner M. 2005. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J. Antimicrob. Chemother. 55:306-311. http://dx.doi.org/30.3093 /jac/dki009.
24. Vainio S, Wilhelm A, Vandenbroucke-Grauls C, Murk JL, Debets- Ossenkopp Y. 2013. Rapid selection of carbapenem-resistant by clinical concentrations of ertapenem. Int. J. Antimicrob. Agents 41:492-494. http: //dx.doi.org/10.1016/j.ijantimicag.2013.01.010.
25. Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ. 2011. The effects of group 1 versus group 2 carbapenems on imipenemresistant Pseudomonas aeruginosa: an ecological study. Diagn. Microbiol. Infect. Dis. 70:367-372. http://dx.doi.Org/10.1016/i.diagmicrobio.2011 .03.009.
26. Nicolau DP, Carmeli Y, Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJC. 2012. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. Int. J. Antimicrob. Agents 39:11-15. http://dx.doi.org/10.1016/j ijantimicag.2011.08.018.
27. Cook PP, Gooch M, Rizzo S. 2011. Reduction in fluoroquinolones use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study. Antimicrob. Agents Chemother. 55:5597-5601. http://dx.doi.org/10.1128/AAC.00742-11.
28. Sousa D, Castelo-Corral L, Gutierrez-Urbón JM, Molina F, López- Calviño B, Bou G, Llinares P. 2013. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology? J. Antimicrob. Chemother. 68:1917-1925. http://dx.doi.org/10.1093/jac/dkt091.